Knocking down the expression of Runx1 in Asxl1−/−Ezh2−/− c-kit+ cells produced an even more aggressive MDS/MPN disease with a shorter latency than Asxl1−/−Ezh2−/− control (supplemental Figure 4F-H). This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.